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Doxorubicin is frequently used in the treatment of
lymphomas; the pegylated liposomal formulation of the
drug (Peg-Doxo) has significantly improved its therapeutic
index, reducing the toxic adverse effects. Peg-Doxo shows a
similar efficacy, being less cardiotoxic, producing less nau-
sea and vomiting and only mild myelosuppression and alo-
pecia (1). The drug, carried in stealth liposomes able to
escape the interception by the immune system, shows a pro-
longed circulation time and a propensity for extravasating
through the leaky vessels of the tumour tissues; it results the
increased concentration of the drug in target tissues and the
decreased toxicity to normal cells (2). Originally approved
for the treatment of metastatic breast cancer, in advanced
ovarian cancer and in Kaposi’s sarcoma, Peg-Doxo has
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been successfully used in other solid tumours and in haema-
tological neoplasms: refractory-relapsed multiple myeloma
(3), indolent non-Hodgkin’s lymphoma (NHL) in mono-
therapy (4), as well as in aggressive lymphoma (5), even in
elderly patients (6, 7), in cyclophosphamide, doxorubicin,
vincristine and prednisone (CHOP) plus rituximab regimen
(8, 9), relapsing Hodgkin’s lymphoma (10). It has been
successfully used also in primary cutaneous lymphomas
(PCLs), which constitute the second most common group
of extranodal NHLs after the gastrointestinal ones, with an
incidence of about 1 per 100 000 inhabitants per year (11).
Peg-Doxo has been successfully used particularly in
primary cutaneous T-cell lymphomas (PCTCLs). The larg-
est study in this setting was conducted in recalcitrant ⁄ recur-
rent PCTCLs. Thirty-four patients received Peg-Doxo
monotherapy (20 mg ⁄m2) and obtained 44% complete
response (CR), 88% overall response (OR) with a disease
free survival (DFS) of 13 months, event free survival (EFS)
of 12 months and overall survival (OS) of 18 months (12).
In another experience, 10 patients with IV B stage Mycosis
Fungoides (MF) obtained three partial responses (PR) and
two stable diseases (SD) with a median OS of five months
(13), while in 2006, were described six relapsing, refractory
MF patients in stage IB-IVA who were treated with
Peg-Doxo monotherapy (20 mg ⁄m2): one patient obtained
a CR, four a PR and one a SD (14). Our experience in 19
advanced and relapsed PCTCLs treated with Peg-Doxo
monotherapy (20 mg ⁄m2) showed an OR and CR rates of
84% and 42% respectively and a mild toxicity (11% grade
III ⁄ IV); after a maximum 46 month-follow-up, median OS,
EFS and PFS survival were 34, 18 and 19 months and the
OS, EFS and PFS rates at 46 months were 44%, 30% and
37% respectively (15). The dose escalation to 40 mg ⁄m2
increases toxic effects, but does not seem to improve the
effectiveness as recently reported in 25 patients (16).
Peg-Doxo has not been evaluated in primary cutaneous
B-cell lymphomas (PCBCLs) to date, which account for
about 25% of all PCLs. According to the recent WHO-EO-
RTC consensus classification, PCBCLs include (11):
primary cutaneous marginal-zone B-cell lymphomas
(PCMZLs), follicle-centre lymphomas (PCFCLs), diffuse
large B-cell lymphomas, leg type (PCLBCLs-LT). More
rare types are diffuse large B-cell lymphoma-other,
lymphoblastic lymphoma and intravascular large B-cell
lymphoma. The therapy of advanced, relapsed or refrac-
tory primary cutaneous B-cell lymphomas is often unsatis-
factory. Systemic polychemotherapy with CHOP or
CHOP-like regimens represent a standard therapy in
PCLBCL (17, 18), and sometimes even in particularly
refractory or relapsing PCMZL and PCFCL especially in
patients presenting with diffuse and numerous cutaneous
lesions (19). Starting from the encouraging results in B-cell
systemic lymphomas and in PCTCLs, we performed a
prospective phase II pilot clinical trial of Peg-Doxo
monotherapy (20 mg ⁄m2) in PCBCL. We report prelimin-
ary results in five patients, which are herein analyzed
together with a review of literature on the treatment of
PCBCL.
Patients and methods
Patients
Five patients, affected by PCBCL, underwent a complete
evaluation including laboratory analyses, clinical history,
physical examination and identification of all skin lesions
as patches, plaques or nodules. The histological diagnoses
have been made or reviewed according to the recent con-
sensus classification (11); besides, the new TNM stagging
system (according to Tumour, Node, Metastasis) was
used (20). Total body CT scan, bone marrow trephine
biopsy and echocardiogram were performed before start-
ing treatment. Ethical approval of the study was granted
and all the patients gave their written informed consent.
Treatment, response and toxicity assessment
All patients received intravenous pegylated liposomal
doxorubicin, Peg-Doxo (Caelyx, Schering-Plough,
Bruxelles, Belgio) at the dosage of 20 mg ⁄m2 every 3–
4 wk, preceded by an antiemetic prophylaxis. Supportive
therapy consisted of oral pyridoxine 300 mg daily from
the beginning of the treatment until 1 month after its dis-
continuation, to prevent the palmar–plantar erythrodys-
esthesia (PPE) or hand–foot (HF) syndrome (21–23).
Responses, which were lasting 4 wk at least, were defined
according to Cheson’s criteria (24) and assessed by two
independent observers who were blind to each other’s
evaluation. Complete remission (CR) was defined as the
complete clearance of all skin lesions, i.e. absence of clin-
ically detectable residual disease; relapse was defined as
any clinically detectable disease after a CR (24). Toxicity
was graded according to the National Cancer Institute
(NCI) Common Terminology Criteria for Adverse Events
(CTCAE), version 3 criteria (25); skin toxicity was partic-
ularly evaluated, as described by Lotem et al. (22).
Results
All patients had multiple skin lesions, without lymph
node involvement and with no evidence of extracutane-
ous non-lymph nodal disease. Three patients had a wide-
spread skin involvement, with numerous lesions
involving ‡3 non-contiguous body regions, T3b accord-
ing to TNM system (20). Two patients had a regional
skin involvement with multiple lesions limited to one or
two contiguous body regions and with all-disease-encom-
passing in a >15-cm and <30-cm-diameter (T2b) or in
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a >30-cm-diameter (T2c) circular area. One was affected
by indolent and four by aggressive PCBCL. In two
patients, the treatment was first-line (Table 1).
Patient 1
A 38-yr-old woman was diagnosed with PCMZL
23 months before; she had been treated with radiother-
apy, followed by gemcitabine for a massive recurrence,
thus achieving a CR. She came with multiple generalized
nodular lesions and grouped plaques on the head, neck,
both lower arms and upper legs and right lower leg
(T3b, N0, M0). The performance status (PS) according
to WHO was 0 and she had no systemic symptoms. The
skin biopsy showed a diffuse dermal infiltrate, not
involving the epidermis, structured in follicles with reac-
tive germinal centers; they were surrounded by small
sized monomorphic lymphocytes with irregular nuclei
and pale cytoplasm, showing a B cell CD20 + immuno-
phenotype, without expression of CD10, BCL6, BCL1,
MUM1 and with low proliferative index (Mib-1 positiv-
ity in 5%), surrounded by a rich plasmacellular popula-
tion, expressing CD138 and CD79a and with monotypic
expression of cytoplasmic immunoglobulin k light chain:
the whole picture was interpreted as a relapse of
PCMZL. The association with Borrelia Burgdorferi infec-
tion was ruled out, both with serological tests and the
molecular detection by PCR-technique analysis in the
formalin-fixed and paraffin-embedded tissues samples, as
previously reported (26). The total body CT scan and
bone marrow trephine biopsy were negative and neither
the t(11;14) and t(14;18) nor BCL1 protein expression
were demonstrated. She was treated with Peg-Doxo
Table 1 Clinico-pathological characteristics of the patients before starting Peg-Doxo treatment, response and follow-up
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Gender F M M M M
Age (yrs) 38 55 53 75 55
Disease history (months) 23 35 10 2 2
WHO ⁄ EORTC
histological type
PCMZL PCLBCL-LT PCLBCL-LT PCLBCL-LT PCLBCL-LT
Pretreatment R; Gem R; R-CVP R None None
Type of lesions Nodules and plaques Nodules and
plaques
Nodules and
plaques
Nodules and
plaques
Nodules
Body regions HN, RLAH, LLAH,
RUL, RLLF, LUL
C, AG UB C, UB, RLLF, LLLF RUA, RLAH
LUA, LLAH
TNM T3b, N0, M0 T2c, N0, M0 T2b, N0, M0 T3b, N0, M0 T3b, N0, M0
PS 0 0 1 1 0
No. infusions 4 8 8 6 6
LDH Normal Normal High High High
b2microglobulin Normal Normal Normal High Normal
Itching No Yes No No Yes
Max response (months) 2 2 3 4 3
Response Complete Complete Complete Complete Complete
Toxicity (grade and type) No No No III neutropenia I neurotoxicity
Relapse (months) Yes (8) No No Yes (11) No
Post-treatment IFN; Rit – – CBVD; Rit –
Status at last follow-up AW; CR AW; CR AW; CR DOD AW; CR
Follow-up (months) 52 69 5 25 63
Pretreatment: R, radiotherapy; Gem, gemcitabine; R-CVP, rituximab, cyclophosphamide, vincristine, prednisone.
Body regions according to TNM system (23): HN, head and neck; C, chest; AG, abdominal and genital; UB, upper back; RUA, right upper arm;
RLAH, right lower arm and hand; LUA, left upper arm; LLAH, left lower arm and hand; RUL, right upper leg; RLLF, right lower leg and feet; LUL,
left upper leg; LLLF, left lower leg and feet.
TNM (23): T2, regional skin involvement: multiple lesions limited to 1 body region or 2 contiguous body regions; T2a, all-disease-encompassing in
a <15-cm-diameter circular area; T2b, all-disease-encompassing in a >15-cm and <30-cm-diameter circular area; T2c, all-disease-encompassing in
a >30-cm-diameter circular area; T3, generalized skin involvement; T3a, multiple lesions involving 2 non-contiguous body regions; T3b, multiple
lesions involving ‡3 body regions. N0, no clinical or pathological lymph node involvement; M0, no evidence of extracutaneous non-lymph node dis-
ease.
PS: performance status according to WHO.
Relapse: time from Peg-Doxo to relapse.
Post-treatment: IFN, interferon; Rit, rituximab; CBVD, Peg-Doxo, bleomycin, vinblastine, dacarbazine.
Status: AW, alive and well; DOD, dead of disease.
Follow-up: months from Peg-Doxo to last follow up or death.
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monotherapy and after four infusions reached a clinical
CR. She relapsed after 8 months and was treated with
interferon, reaching a PR, i.e. reduction ‡50% of pre-
existing skin lesions and also ‡50% resolution of nodules
and plaques in macular lesions, with no evidence of new
lesions. The CR was obtained through a consolidation
with systemic rituximab. A second relapse was success-
fully treated with rituximab, achieving a CR, now still
lasting 52 months after Peg-Doxo therapy.
Patient 2
A 55-yr-old man, PS 0, affected by PCLBCL-LT, firstly
diagnosed 35 months before, had been successfully previ-
ously treated with radiotherapy and R-CVP chemother-
apy (rituximab and cyclophosphamide, vincristine,
prednisone). He presented multifocal itching plaques and
tumours on the chest and abdomen (T2c, N0, M0). The
cutaneous biopsy specimen showed a diffuse monotonous
population of blasts with round nuclei, extending into the
subcutaneous tissue; the blasts were immunoreactive for
CD20, expressed BCL2, MUM1, showed a high prolifera-
tive index (Mib-1 positivity in 75% of cells) and were neg-
ative for BCL6. All the staging procedures were negative,
the diagnosis of PCLBCL-LT was confirmed and Peg-
Doxo treatment started, with eight infusions. The patient
reached a CR after 2 months, still lasting 69 months later.
Patient 3
A 53-yr-old man, PS 1, was affected by PCLBCL-LT,
previously treated with radiotherapy. He presented grow-
ing nodules and plaques on upper back, i.e. T2b, N0,
M0. The histological examination revealed a diffuse infil-
trate of large round cells, positive for CD20, MUM1,
with a variable expression of BCL6 and focal expression
of BCL2, which was interpreted as a phenotypic variant
of LBCL-LT. He was treated with eight courses of Peg-
Doxo and reached a CR.
Patient 4
A 75-yr-old man, PS 1, presented multifocal rapidly
growing plaques and tumours of 3–4 cm on the chest,
upper back, both lower legs and feet, without systemic
symptoms (Fig. 1). He belonged to T3b, N0, M0 group.
The biopsy specimen showed a diffuse monotonous popu-
lation of blasts with immunoblastic appearance involving
the skin and infiltrating the epidermis; they were diffusely
positive for CD20, negative for CD10, positive for BCL6,
BCL2, MUM1, and highly proliferating with an elevated
Mib-1 immunostaining (Fig. 2). The diagnosis was
PCLBCL-LT. He started Peg-Doxo therapy and obtained
a very good partial remission (VGPR) after only two
cycles, i.e. a reduction >75% of skin lesions and also
>75% resolution of nodules and plaques in macular
lesions, with no evidence of any new lesions (Fig. 3). A
clinical and histological CR was reached after six cycles,
so the patient received a maintenance therapy with inter-
feron. The first cutaneous recurrence occurred after
11 months and was treated with four courses of CBVD
scheme (peg-doxo 12 mg ⁄m2, bleomycin, vinblastine, da-
carbazine), followed by rituximab, again resulting in a
clinical and histological CR. After 4 months, a second
relapse was recorded, showing the same histopathological
A B C
D E
F G
Figure 1 Patient number 4: PCLBCL-LT. A
75-yr-old man presented multifocal rapidly
growing infiltrating plaques and tumours of
3–4 cm on the trunk (A, B, D) and both lower
legs (C, E, F, G).
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pattern as at diagnosis. Besides the cutaneous lesions, the
patient presented a progressive headache. A brain CT
scan and then MRI revealed in the left side of the corpus
callosum a nodular lesion of 2.5 cm, with a homogeneous
enhancement after i.v. administration of contrast med-
ium; besides, other hyperintense in T2-weighted lesions,
with inhomogeneous enhancement after contrast medium,
were localized in left frontal lobe, the paraventricular left
region along the internal capsule and the subependymal
tissue of right fourth ventricle; the cerebrospinal fluid and
the bone marrow were normal. The 18FDG-CT ⁄PET
showed foci of high hyperactivity in correspondence of
the corpus callosum and in paramedian posterior right
region of the fourth ventricle, a cerebral PCBCL localiza-
tion was considered most likely. Brain radiotherapy was
started, but a few days later, the patient developed pneu-
monia and died because of pulmonary embolism,
27 months after the first diagnosis.
Patient 5
A 55-yr-old man, PS 0, came to our attention with a
1-month-history of rapidly growing multiple diffuse itch-
ing nodules of both upper and lower arms, whose histo-
pathological examination revealed the aggressive pattern,
confirmed by immunohistochemical detection of CD20,
BCL6, BCL2, MUM1 and elevated Mib-1. The man was
affected by PCLBCL-LT, stage T3b, M0, N0, according
to TNM classification. He was treated with six courses
of Peg-Doxo monotherapy, which was well tolerated,
and a CR was reached still lasting after 63 months.
Toxicity
Peg-Doxo monotherapy was well-tolerated and in no
patient, the dose was decreased or the infusion was
delayed (Table 1). One patient had a reversible mild
A B C
D E F
Figure 2 Patient number 4: PCLBCL-LT.
Diffuse large B-cell lymphoma involving the skin
and infiltrating the epidermis; cells are large
blasts with immunoblastic appearance (H and
E) (A). Blasts are diffusely positive for CD20 (B),
negative for CD10 (C), positive for BCL6 (D),
BCL2 (E), and highly proliferating with Mib-1
immunostaining (F).
A B C
D E F
Figure 3 Patient number 4: PCLBCL-LT. At
diagnosis (A, D), after two cycles of Peg-Doxo
monotherapy (B, E), after four cycles of
Peg-Doxo (C, F). A, B, C: lower legs; D, E, F:
trunk.
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grade I neurotoxicity; the haematological toxicity was
mild with one case of grade III neutropenia successfully
treated with granulocyte colony-stimulating factor
(G-CSF). Nobody experienced a dermatological toxicity
(22), like follicular rash, intertrigolike eruption or the
formation of melanotic macules; in particular, the pal-
mar–plantar erythrodysesthesia, frequently reported in
patients treated with Peg-Doxo, was not recorded
(21–23).
Discussion
The present study constitutes the first report on pegylat-
ed liposomal doxorubicin in patients affected by primary
cutaneous B-cell lymphomas. A monochemotherapy with
Peg-Doxo at the dosage of 20 mg ⁄m2 has been used. All
the five patients achieved a complete response
(CR = 100%), in a short period (median 3 months),
even when they had been pretreated with radio-chemo-
therapy or when experiencing the most aggressive forms,
like PCLBCL-LT. The treatment was well-tolerated and
safe, confirming that Peg-Doxo ameliorates the common
side effects of conventional doxorubicin (2). Severe
mucocutaneous reactions, however, can occur with
repeated doses of Peg-Doxo, mostly the palmar–plantar
erythrodysesthesia (PPE) or hand-foot (HF) syndrome,
as Peg-Doxo has a particular skin-tropism suggested by
pharmacokinetic studies (1, 21). The PPE is character-
ized by tingling, dysesthesia, erythema and swelling, fol-
lowed in severe cases by skin desquamation, crusting,
ulceration and necrosis of the epidermis; it affects hands,
feet and other skin areas under prolonged friction or
pressure (21, 22). Different pathophysiological mecha-
nisms are suggested: Peg-Doxo, excreted from sweat
glands, penetrates into the corneum stratum producing
local oxidative and inflammatory reactions; it has a
direct cytotoxic effect or it is extravasated from the deep
microvessels through the local pressure. PPE incidence is
dose- and schedule-dependent and influenced by peak
drug concentration, total cumulative dose and infusion
time (21–23). It is reversible with complete healing and
is unrelated to chemotherapy vesicant effect. PPE is fre-
quently reported in patients with cancer treated with
Peg-Doxo: about 50% of all patients with solid neo-
plasms, who received the currently approved dose of
50 mg ⁄m2 every 4 wk, experienced PPE and about 20%
of them a grade III PPE. When PPE develops, Peg-Doxo
dose reduction, schedule modification, ultimately drug
withdrawal are considered; some authors have suggested
prophylaxis or treatment with pyridoxine, dexametha-
sone, amifostine and celecoxib (21). In our patients, the
PPE did not occurred; probably, it was prevented by the
prophylaxis with pyridoxine, as well as by the utilization
of lower dosages in monochemotherapy of Peg-Doxo,
compared with the higher doses and to the polychemo-
therapeutic regimes commonly used in other solid neo-
plasms.
For a comparison of our results with the common
treatment modalities applied in PCBCL, it is not surpris-
ing to find in the literature the absence of controlled and
randomized trials in PCBCL. Very recently, EORTC,
Cutaneous Lymphoma Group and the International
Society for Cutaneous Lymphomas published consensus
recommendations for the management of the main
groups of PCBCL; they are mainly based on retrospec-
tive studies and small cohort studies (27). Besides chemo-
therapy, the most widely accepted treatments of PCBCLs
are the complete excision of localized lesions (27), radio-
therapy (28), topical or intralesional steroids (29), sys-
temic and intralesional interferon-a and interferon-c (30),
rituximab (31, 32). More experimental therapies include
denileukin diftitox (33), new biological agents (29, 34)
and Yttrium-90-ibritumomab tiuxetan or 131I-tositumo-
mab radioimmunotherapy (29, 35).
In indolent primary cutaneous B-cell lymphomas, i.e.
PCMZL and PCFCL, one or few localized small lesions
can be cured surgically through a complete excision; in
some studies, about 95% of the patients obtained a CR,
although 50% of them developed new skin lesions; a bet-
ter definition of tumour-resection free margins is proba-
bly necessary (27). Topical or intralesional steroids can
be used to treat patients with individual symptomatic
skin lesions (29). Systemic and intralesional interferon-a
and interferon-c have been reported, with dosages from 1
to 6 million IU three times a week, according to the
extent of the lesions (30). Similar to the gastric MALT
lymphoma treatment where the aim of therapy is to
eradicate Helicobacter pylori infection, in PCMZL
patients, the eradication of Borrelia burgdorferi infection
– if any – by specific antibiotic therapy, especially sys-
temic cephalosporins, often allows a complete remission
(26, 36). Many authors suggest that this therapy should
be always used before more aggressive treatments, but
the efficacy of antibiotics is not well-documented (37).
Like in nodal indolent NHL, in PCMZL and PCFCL
patients, a wait and see policy can be sometimes consid-
ered for the initial management, with subsequent radio-
therapy towards one or few symptomatic skin lesions
(27). In the great majority of these patients, the chemo-
therapy is not considered as first line treatment (28).
Since past years, there was a general consensus that
PCBCLs presenting with solitary or localized skin lesions
should be treated with optimal dose of radiotherapy,
irrespective of histological type, as they have a good
prognosis and very rarely develop extracutaneous
relapses. The optimal therapy for patients showing multi-
focal skin nodules or plaques appeared more problematic
with some reports describing an unfavourable prognosis
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in the multifocal PCBCLs; consequently, many suggested
an aggressive multiagent chemotherapy. Recent studies
revealed that in PCFCL and PCMZL, even when
presenting with lesions at different sites, the irradiation
of all visible skin lesions, with multiple radiation fields,
may be preferable to chemotherapy, because of less
toxicity and similar effectiveness, as these patients share
the same low tendency to develop extracutaneous disease
and the same good prognosis of individuals with local-
ized skin lesions (19). The reported cumulative doses per
irradiation field are mostly between 20 and 45 Gy. In
almost all patients with PCMZL treated with radiother-
apy, an initial CR was observed, even if about 50% of
patients showed a cutaneous relapse, while extracutane-
ous progression being very rare. Moreover, new cutane-
ous lesion can be frequently treated with the same
therapy used as first line. The largest studies in PCFCL
described a relapse in about 30% of patients (28, 38).
Multifocal PCFCLs occurring in the leg have a worse
prognosis than PCFCL at other sites, similar to PCBCL-
LT (18). In patients with indolent PCLs, systemic chemo-
therapy may be effective in yet particularly recalcitrant,
refractory and relapsing forms, especially presenting with
widespread, numerous and extremely thick tumours
occurring in non-related parts of the skin, in which
radiotherapy seems to be unsuitable (19). In a recent
review among 300 PCBCL patients, only 7% to 14%
among indolent types underwent chemotherapy (18).
Among chemotherapeutic agents, chlorambucil may be
used in relapsing and ⁄or multifocal skin lesions of
PCMZL and in particular, in the elderly, in patients with
diffuse skin lesions, a 50% rate of CR has been reported
(37, 39). Local chemotherapy has been used in the past
for PCLs: intralesional cisplatin gel in PCFCLs (40) or
topical carmustine (BCNU), more commonly used in
PCTCL (41). Reports about agents used in indolent
nodal B-cell NHL, like fludarabine, cladribine and
pentostatin are lacking in PCBCL. Few data exist about
polychemotherapy in indolent PCLs; in PCMZL, in
particular, it is very rare; CHOP or CHOP like regimens
have been used. Rituximab has been used in both
PCMZL and PCFCL as systemic treatment at the dosage
of 375 mg ⁄m2 i.v. once weekly and as topical intralesional
treatment at the dosage of 5–30 mg per application once
or 2–3 times a week. Intralesional rituximab resulted safe
and effective, similar to i.v. therapy. It can induce a com-
plete disappearance of B-cells in the peripheral blood,
suggesting a systemic effect (31); nevertheless relapse of
CBCL with new lesions at distinct sites can be observed
more frequently after intralesional treatment (32). The
patient 1 constitutes an example of an indolent form,
PCMZL, but with an extensive skin involvement, previ-
ously already treated, in which radiotherapy was consid-
ered inappropriate and a systemic treatment was
therefore necessary. Peg-Doxo showed a good clinical
outcome, although it probably did not change the natu-
ral history of the disease, which is a frequently relapsing
cutaneous disease. More investigations in indolent
PCBCL are required.
The primary cutaneous large B-cell lymphomas
(PCLBCLs) represent a separate group including the leg-
type and other, with a general unfavourable prognosis,
because of a different genetic pattern expression, like
BCL2 and Fas-ligand (18, 42). PCLBCL-LT predomi-
nantly affects elderly patients, has a high tendency to
extracutaneous dissemination and a high mortality rate;
the presence of multifocal skin lesions might represent
an additional risk factor. Less aggressive therapies are
sometimes compulsory because of the advanced age or
the presence of different comorbidities in the patients,
but they never result in a sustained CR. In the recent
review among 300 PCBCL patients, up to 25% of
aggressive ones (PCLBCL) underwent chemotherapy
(18). Before the eighties, patients with localized
PCLBCL were treated only with radiotherapy, but later,
the treatment was changed to doxorubicin-containing
regimens, an approach giving results well-correlated with
the concepts and outcomes of early Ann-Arbor stage of
all sites (stage IE) (17, 43). Only very localized PCLBCL
in older patients, not suitable for aggressive treatment,
could be managed through an irradiative treatment. It is
not clear if radiotherapy should be proposed as standard
treatment in such rare cases presenting with a small soli-
tary lesion (27). On the contrary, the most commonly
described PCLBCLs presenting with multifocal lesions
must be treated with systemic chemotherapy, sometimes
completed with adjuvant radiotherapy. CHOP or
CHOP-like regimens constitute the golden standard
among the polychemoterapeutic schemes: in 46 PCBCL,
the OR rate was 98% with 89% CR rate and 33%
relapse rate (44). CHOP regimen appears to be preferred
to COP as it reduces relapse rates (43). A case has been
successfully treated with MACOP-B polychemoterapy
showing a good response and a DFS of more than 3 yr
(45). Even the systemic administration of rituximab
appears a good chance, in particular, in the elderly; in
very aggressive or in plurirelapsing lymphomas, in case
with systemic involvement, the combination of rituximab
with anthracycline-containing chemotherapies may be
proposed, even if data about response and prolonged
follow-up are still lacking (17, 31). The association of
rituximab with single-dose cyclophosphamide in seven
relapsing PCBCL gave encouraging results, even if a
short follow-up period has been reported, in particular
in terms of DFS, with OR rate of 85% and CR 71%
(46).
Finally, in exceedingly rare aggressive, refractory or
plurirelapsing PCBCLs, the autologous and even
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allogeneic bone marrow as well as stem cell transplanta-
tion can be proposed, even if these procedures are associ-
ated with significant morbidity and mortality, especially
in the elderly (47).
Among our patients, all the four with aggressive forms
(PCLBCL-LT) showed a CR in a short period, which
was long lasting in two of them (69 and 63 months
respectively), even if one of them had a refractory,
relapsing disease (Patient 2). The particular skin-tropism
of Peg-Doxo (1, 21) probably accounts for the high rate
of CR in such very aggressive cutaneous lymphoma. The
patient 4 died for relapsing and progressive disease. He
constitutes a rare example of extracutaneous recurrence
in the central nervous system (CNS). The overall risk of
secondary CNS involvement in NHL is about 5%. With
regards to PCLs, this complication is mainly reported in
patients with PCTCL, mostly in stage IV B Mycosis
Fungoides and, among B histological types, in intra-
vascular lymphoma, but very rarely in other PCBCL,
which accounts for 2% of cases and is related to death,
according to the published data from the Dutch Cutane-
ous Lymphoma Registry (48, 49).
In conclusion, as regarding this prospective phase II
pilot clinical trial, monotherapy with Peg-Doxo shows a
significantly high clinical activity and a good safety pro-
file in PCBCLs, compared with other mono- and poly-
chemotherapeutic regimens reported in the literature,
The major limitations of this pilot study are that the
case-number is small and that one patient has a very
short follow-up period (5 months); on the contrary, the
other three alive patients have quite long follow-up per-
iod (52, 69 and 63 months respectively). It suggests the
need of further and extended investigations in PCBCLs,
even randomized studies. The association of Peg-Doxo
with other drugs, especially rituximab, should be consid-
ered.
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